Cardiovascular diabetology, 2018-06, Vol.17 (1), p.94-22, Article 94
2018
Details
- Autor(en) / Beteiligte
- Titel
- Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy
- Ist Teil von
- Cardiovascular diabetology, 2018-06, Vol.17 (1), p.94-22, Article 94
- Ort / Verlag
- England: BioMed Central
- Erscheinungsjahr
- 2018
- Link zum Volltext
- Quelle
- Free E-Journal (出版社公開部分のみ）
- Beschreibungen/Notizen
- Patients with diabetes type 2 have an increased risk for cardiovascular disease and commonly use combination therapy consisting of the anti-diabetic drug metformin and a cholesterol-lowering statin. However, both drugs act on glucose and lipid metabolism which could lead to adverse effects when used in combination as compared to monotherapy. In this review, the proposed molecular mechanisms of action of statin and metformin therapy in patients with diabetes and dyslipidemia are critically assessed, and a hypothesis for mechanisms underlying interactions between these drugs in combination therapy is developed.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1475-2840eISSN: 1475-2840DOI: 10.1186/s12933-018-0738-4Titel-ID: cdi_doaj_primary_oai_doaj_org_article_65bd2dacec0245e2a690c08c867d1a4f
- Format
- –
- Schlagworte
- Animals, Antidiabetics, Atherosclerosis, Atorvastatin, Biomarkers - blood, Blood Glucose - drug effects, Blood Glucose - metabolism, Cardiovascular disease, Cardiovascular diseases, Cardiovascular Diseases - blood, Cardiovascular Diseases - diagnosis, Cardiovascular Diseases - epidemiology, Cardiovascular Diseases - prevention & control, Cholesterol, Combination therapy, Diabetes, Diabetes mellitus, Diabetes mellitus (non-insulin dependent), Diabetes Mellitus, Type 2 - blood, Diabetes Mellitus, Type 2 - diagnosis, Diabetes Mellitus, Type 2 - drug therapy, Diabetes Mellitus, Type 2 - epidemiology, Drug dosages, Drug Interactions, Dyslipidemia, Dyslipidemias - blood, Dyslipidemias - diagnosis, Dyslipidemias - drug therapy, Dyslipidemias - epidemiology, Glucose, Glucose metabolism, Health risks, Heart, Humans, Hydrogen bonds, Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects, Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics, Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use, Hyperglycemia, Hypoglycemic Agents - adverse effects, Hypoglycemic Agents - pharmacokinetics, Hypoglycemic Agents - therapeutic use, Insulin resistance, Lipid metabolism, Lipid Metabolism - drug effects, Lipids, Lipids - blood, Lipoproteins, Metabolic disorders, Metabolic syndrome, Metformin, Metformin - adverse effects, Metformin - pharmacokinetics, Metformin - therapeutic use, Molecular chains, Molecular modelling, Review, Risk Factors, Simvastatin, Statins, Treatment Outcome, Triglycerides, Type 2 diabetes